| Literature DB >> 24023581 |
Abdulrahman L Al-Malki1, Ahmed Amir Radwan Sayed, Haddad A El Rabey.
Abstract
Hyperlipidemia and hyperglycemia result in oxidative stress and play a major role in the development of diabetic nephropathy (DN). We explored the effects of proanthocyanidin (PA) on the induction and progression of DN in apolipoprotein E-deficient mice. Diabetes Mellitus was induced in ten-week-old male apoE(-/-)mice using streptozotocin (STZ). Mice were fed with a high-fat diet in presence or absence of PA. PA treatment significantly reduced the high cholesterol levels, restored renal functions, and reduced albuminuria in the PA-treated diabetic mice compared with the diabetic untreated mice. In addition, the glomerular mesangial expansion in the diabetic mice was attenuated as a result of PA supplementation. Moreover, PA treatment restored the elevated levels of MDA and CML and the reduced activity of SOD and GSH in the diabetic mice. Furthermore, PA feeding reduced the activation and translocation of NF- κ B to the nucleus compared with the diabetic untreated animals. Reduction of NF- κ B activation resulted in the attenuation of the expression of IL-6, TGF β , and RAGE which protected PA-treated mice against DN. The renoprotective effects of PA were found to be time independent regardless of whether the dietary feeding with PA was started pre-, co-, or post-STZ injection. In conclusion, part of the beneficial effects of PA includes the disruption of the detrimental AGE-RAGE-NF κ B pathways.Entities:
Year: 2013 PMID: 24023581 PMCID: PMC3759251 DOI: 10.1155/2013/769409
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Effects of STZ treatment and dietary PA feeding on the food intake, bodyweight, albuminuria, biochemical parameters, serum AGE, TNFα, IL-6, GSH, and 8-hydroxy-2′-deoxyguanosine of apolipoprotein E-deficient mice.
| Control | Control + PA | Diabetic | Diabetic + PA | |
|---|---|---|---|---|
| Initial bodyweight, g | 195.13 ± 9.5 | 196.33 ± 6.5 | 196.44 ± 7 | 197 ± 7.2 |
| Final bodyweight, g | 265.5 ± 8.2 | 234 ± 12.3a,b | 161.8 ± 7.2a | 215.52 ± 8.9a,b |
| Glucose, mg/dL | 92.78 ± 0.45 | 96.21 ± 0.57a,b | 265.35 ± 1.45a | 106.71 ± 1.23b |
| HbA1c, % | 5.24 ± 0.41 | 6.88 ± 0.52b | 9.42 ± 0.34a | 6.85 ± 0.38b |
| Albumin, g/L | 38.4 ± 5.7 | 38.9 ± 8.1 | 38.2 ± 7.7 | 38.7 ± 7.5 |
| Total protein, g/L | 76 ± 7 | 69.91 ± 7.5b | 62 ± 6.5a | 65.6 ± 7.1 |
| GSH, mmol/L | 0.281 ± 0.015 | 0.172 ± 0.02a,b | 0.105 ± 0.03a | 0.145 ± 0.021a,b |
| Catalase, U/g Hb | 94.54 ± 14 | 86.55 ± 12b | 50.98 ± 15a | 70.11 ± 11a,b |
| Glutathione reductase, U/gHb | 4.25 ± 0.09 | 3.21 ± 0.94b | 2.25 ± 0.62a | 2.54 ± 0.54a,b |
| Glutathione peroxidase, U/gHb | 57.1 ± 11 | 69.9 ± 9.55b | 145.5 ± 45a | 89.54 ± 10.2b |
Data shown represent mean ± SE of mice, 12 weeks after the treatment with STZ or with the buffer (control) in presence or absence of PA. a,bSignificance difference between groups.
Oxidant/antioxidant parameters as well as concentration of carboxymethyl lysine (CML) in rat retinas.
| Control | Control + PA | Diabetic | Diabetic + PA | |
|---|---|---|---|---|
| MDA, nmol/mg protein | 2.45 ± 0.16 | 2.95 ± 0.15b | 4.75 ± 0.17a | 2.95 ± 0.15b |
| GST, nmol substrat·mg protein−1·min−1 | 176 ± 31 | 151 ± 9a,b | 82 ± 13a | 151 ± 9a,b |
| GSH-Px, nmol substrat·mg protein−1·min−1 | 0.92 ± 0.17 | 0.82 ± .165b | 0.34 ± 0.09a | 0.82 ± .165b |
| Catalase, IU·mg protein−1 | 2.61 ± 0.032 | 1.45 ± 0.21a,b | 0.52 ± 0.03a | 1.45 ± 0.21a,b |
| SOD, nmol substrat·mg protein−1·min−1 | 3.53 ± 0.45 | 2.95 ± 0.75b | 1.82 ± 0.35a | 2.95 ± 0.75b |
| GSH, nmol/mg protein | 16 ± 3 | 16 ± 2.3 | 16.11 ± 2 | 16 ± 2.3 |
| CML, pg/mg protein | 3.54 ± 0.22 | 3.2 ± 0.6b | 8.81 ± 0.34a | 3.2 ± 0.6b |
Oxidative stress markers in the kidney homogenate of apoE−/mice. Mice treated either with or without STZ in presence or absence of PA. PA treatment was continued for 12 weeks after the onset of diabetes. Data shown represent mean ± SEM. a,bSignificance difference between groups.
Figure 1NF-κB activation in the rat kidney: Western blot of rat kidneys of control rats, control rats + PA, diabetic rats, and diabetic rats treated with PA. Cytoplasmic (A) and nuclear (B) extracts were obtained as described in the Materials and Methods section.
Figure 2Nephrin mRNA expression (a), TGFβ1 (b), RAGE (c) and SOD2 (d) expressions were measured using ELISA kit. Kidneys and sera were obtained from all groups treated with saline and PA and mice pretreated with different concentrations of proanthocyanidin. Mean values ±SD are shown. The asterisk (*) values are different (P < 0.05) as compared with control group.
Figure 3Mesangial expansion and ultrastructural changes in diabetic apoE−/mice after 12 weeks after induction of diabetes mellitus. (a) Nondiabetic mice without PA. (b) Diabetic mice without PA. (c) Diabetic mice with PA. PAS staining, original magnification ×200.